Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults

References

• Larson RA. Acute lymphoblastic leukemia: Older patients and newer drugs. Hematology. 2005;2005(1):131–136.
   Google Scholar
• Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol. 2009;46(1):64–75.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Foa R. Chemotherapy-free and reduced intensity approaches in elderly patients with B-lineage acute lymphoblastic leukemia. Eur J Intern Med. 2018;58:22–27.
   PubMed Web of Science ®Google Scholar
• Gokbuget N. Treatment of older patients with acute lymphoblastic leukemia. Hematology. 2016;2016:573–579.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19(2):240–248.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847.
   PubMed Web of Science ®Google Scholar
• Horton TM, Gannavarapu A, Blaney SM, et al. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006;58(1):13–23.
   PubMed Web of Science ®Google Scholar
• Cloos J, Roeten MSF, Franke NE, et al. (Immuno)proteasomes as therapeutic target in acute leukemia. Cancer Metastasis Rev. 2017;36(4):599–615.
   PubMed Web of Science ®Google Scholar
• Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol. 2001;28(6):613–619.
   PubMed Web of Science ®Google Scholar
• Csizmar CM, Kim D-H, Sachs Z. The role of the proteasome in AML. Blood Cancer J. 2016;6(12):e503.
   PubMed Web of Science ®Google Scholar
• Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA. 2002;99(25):16220–16225.
   PubMed Web of Science ®Google Scholar
• Nakajima W, Hicks MA, Tanaka N, et al. Noxa determines localization and stability of mcl-1 and consequently ABT-737 sensitivity in small cell lung cancer. Cell Death Dis. 2014;5:e1052–10.
   PubMed Web of Science ®Google Scholar
• Craxton A, Butterworth M, Harper N, et al. Noxa, a sensor of proteasome integrity, is degraded by 26S proteasomes by an ubiquitin-independent pathway that is blocked by MCL-1. Cell Death Differ. 2012;19(9):1424–1434.
   PubMed Web of Science ®Google Scholar
• Messinger YH, Gaynon PS, Sposto R, Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: therapeutic advances in childhood leukemia & Lymphoma (TACL) Study. Blood. 2012;120(2):285–290.
   PubMed Web of Science ®Google Scholar
• Attar EC, DeAngelo DJ, Supko JG, et al. Phase I and pharmacokinetics study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008;14(5):1446–1454.
   PubMed Web of Science ®Google Scholar
• Attar EC, Johnson JL, Amrein PC, et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to Intermediate-Dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60–75 years: CALGB (alliance) study 10502. J Clin Oncol. 2013;31(7):923–929.
   PubMed Web of Science ®Google Scholar
• Kumar S, Moreau P, Hari P, et al. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol. 2017;178(4):571–582.
   PubMed Web of Science ®Google Scholar
• Brayer J, Baz R. The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. Ther Adv Hematol. 2017;8(7):209–220.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951.
   PubMed Web of Science ®Google Scholar
• Foa R, et al. Dasatinib as first-line treatment for adult patients with philadelphia chromosome–positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521–6528.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Douer D. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia. Blood. 2020;135(13):987–995.
   PubMed Web of Science ®Google Scholar
• Brodersen LE, Hudson CA, Alonzo TA, et al. Newly diagnosed childhood AML patients treated with bortezomib show superior survival if CD74 is expressed: a report of 991 patients from the children’s oncology group AAML 1031 protocol [abstract]. Blood. 2020;136(Supplement 1):39–39.
   Web of Science ®Google Scholar
• Teachey DT, Devidas M, Wood BL, et al. Cranial radiation can be eliminated in most children with T-cell acute lymphoblastic leukemia (T_ALL) and bortezomib potentially improves survival in children with T-cell lymphoblastic lymphoma (T-LL): results of children’s oncology group (COG) trial AALL1231[abstract]. Blood. 2020;136(Supplement 1):11–12.
   PubMed Web of Science ®Google Scholar
• Forgione MO, McClure BJ, Eadie LN, et al. KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease. Cancer Lett. 2020;469:410–418.
   PubMed Web of Science ®Google Scholar
• Yokoyama A. Molecular mechanisms of MLL-associated leukemia. Int J Hematol. 2015;101(4):352–361.
   PubMed Web of Science ®Google Scholar
• Stanulla M, Cave H, Moorman AV. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? Blood. 2020;135(4):252–260.
   PubMed Web of Science ®Google Scholar
• Marke R, van Leeuwen FN, Scheijen B. The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2018;103(4):565–574.
   PubMed Web of Science ®Google Scholar
• Maury S, Chevret S, Thomas X, for GRAALL, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375(11):1044–1053.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–753.
   PubMed Web of Science ®Google Scholar